受创新药行情驱动,可T+0交易的恒生医药ETF(159892)持续突破阶段高点,年内涨幅一度超44%,在全市场ETF中涨幅靠前。6月4日早盘,受重仓股信达生物大涨等带动,恒生医药ETF一度涨超4%,泰格医药、再鼎医药、石药集团等领涨。在近期召开的ASCO年会上,信达生物公布了IBI363治疗晚期非小细胞肺癌临床PoC的研究数据,引发市场高度关注。每日经济新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.